Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bemarituzumab (FPA144) in Advanced Solid Tumors
NCT02318329Phase 1Completed
- Sponsor
- Five Prime Therapeutics, Inc.
- Start
- Nov 2014
- Primary completion
- Feb 2019
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label trial of bemarituzumab in solid tumor, gastric cancer (GC), gastroesophageal junction adenocarcinoma and 1 more (3 arms), sponsored by Five Prime Therapeutics, Inc. Primary endpoints: Dose-limiting Toxicities at 4 weeks and Adverse Events at 16 weeks. Started Nov 2014; status: completed.
02
Drugs
bemarituzumab
03
Conditions
solid tumorgastric cancer (GC)gastroesophageal junction adenocarcinomatransitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on NCT02318329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02318329.